Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Pregabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 1.00 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pregabalin SCHEMBL1561104 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL15497 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL263450 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL27754092 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2370227 | 1.00 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2966808 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL4608711 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL17825547 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL19031786 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL3371102 | 0.98 | CACNA2D1 (0.96) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32195 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747280-A2 | METHODS FOR TREATING MULTIPLE MYELOMA | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260132100-A1 | Method for Purifying Pregabalin | ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124211-A1 | COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0830338-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| EP-0828704-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1998003167-A1 | ISOBUTYLGABA AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN | WARNER-LAMBERT COMPANY (US) | 1998-01-29 | — | — | WO | claimed |
| US-5637767-A | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid | WARNER-LAMBERT COMPANY (US) | 1997-06-10 | — | — | US | claimed |
| US-5616793-A | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid | WARNER-LAMBERT COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| WO-1996040617-A1 | METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996038405-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| US-5563175-A | GAMMAAMINOBUTYRIC ACID DERIVATIVE; NERVOUS SYSTEM DISORDERS | NORTHWESTERN UNIVERSITY (US) | 1996-10-08 | — | — | US | claimed |